Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Q3 earnings recap: Winners, losers & surprises

    Q3 earnings recap: Winners, losers & surprises

    FromBioSpace

    Start listeningView podcast show

    Q3 earnings recap: Winners, losers & surprises

    FromBioSpace

    ratings:
    Length:
    18 minutes
    Released:
    Nov 8, 2023
    Format:
    Podcast episode

    Description

    This week (our inaugural episode!) BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the good, the bad and the ugly of biopharma's reported Q3 earnings. They also tackle what's going on at Pfizer, ADCs, deals and more.
    Want to dive deeper on BioSpace? Read more on Pfizer's recent cuts⁠ as part of their cost-savings program and more insight on Q3 earnings for Gilead, ⁠⁠Novo Nordisk,⁠⁠ ⁠⁠Moderna⁠⁠, ⁠⁠Vertex⁠⁠, ⁠⁠BMS⁠⁠, ⁠⁠Lilly,⁠⁠ ⁠⁠GSK⁠⁠.
    Meanwhile, industry-wide ⁠layoffs⁠ march on and in case you missed it - bankruptcies reached a record high.
    Released:
    Nov 8, 2023
    Format:
    Podcast episode

    Titles in the series (46)

    Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.